Fierce Pharma
AUGUST 27, 2024
In June, when the Supreme Court voted 6-3 to overturn the Chevron doctrine, it brought significant impact for the healthcare industry and federal regulators like the FDA and the Centers for Medicare & Medicaid Services. An expert recently discussed the ramifications of the ruling during a Fierce Pharma podcast interview.
MedCity News
AUGUST 21, 2023
Healthcare M&A deals are expected to pick up over the next few months, and one expert is predicting that the biopharma sector in particular will see especially robust activity.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
JUNE 11, 2024
Amid a recent biopharma M&A resurgence, one major player plans to stay out of the waters after making multiple recent splashes.
European Pharmaceutical Review
JULY 7, 2023
New recommendations to boost the competitiveness in UK biopharma and Medtech sectors have been published by Imperial College London. Technological solutions and policy recommendations for government have been identified as a way to help make sectors such as biopharma and Medtech more innovative and increase their value added.
Fierce Pharma
JANUARY 8, 2024
Biopharma companies looking to maximize the visibility of their M&A activity often reveal deals during the J.P. Morgan Healthcare Conference. | In it’s annual Firepower report, EY says the biopharma industry enters 2024 with the capability and motivation to increase M&A activity.
Fierce Pharma
JANUARY 3, 2024
Morgan Healthcare Conference rolled on in San Francisco, BioNTech, Alnylam and many other companies updated investors on their strategies heading into 2024. As the J.P. | As the J.P.
MedCity News
FEBRUARY 16, 2024
Equal parts networking and curated panels covering the latest trends in healthcare investment, MedCity INVEST 2024 is the ideal event to discuss health tech, biopharma, devices and diagnostics investment opportunities. Register today!
Expert insights. Personalized for you.
285 
Let's personalize your content